

GP 1648

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE INDICATED BELOW.


BY: Martha O. Sklar

DATE: August 19, 1998

**PATENT**  
**BOX NON-FEE AMENDMENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: Patent Application of James A. Hoxie : Group Art Unit: 1648  
Appln. No.: 08/882,435 :  
Filed: June 25, 1997 :  
For: ANTIBODIES DIRECTED AGAINST : Attorney Docket  
CELLULAR CORECEPTORS FOR : No. 9596-11U1  
HUMAN IMMUNODEFICIENCY VIRUS : (I-1470)  
AND METHODS OF USING THE SAME :



#128 9/6/98  
T. Boy

RECEIVED  
AUG 31 PAID  
GROUP 1800

**AMENDMENT**

This Amendment responds to the Office Action dated May 22, 1998 (Paper No. 11), sent in connection with the above-referenced application. In response to the Office Action, kindly amend the application as follows.

**In the Claims:**

Please amend claim 1, without prejudice, as follows:

B' 1. (Amended) An anti-immunodeficiency virus antibody which binds to a [cellular protein] chemokine receptor protein essential for immunodeficiency virus entry into a cell wherein said chemokine receptor protein is not CD4.

Please cancel claim 3 without prejudice.

**REMARKS**

The invention relates to the discovery of a novel antibody which inhibits entry of HIV into cells and which specifically binds to a cellular chemokine receptor protein.

Claims 1-2 and 4-10 are pending in the application. Claim 3 has been canceled as being redundant in view of amended claim 1.